Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

ClinicalTrials.gov ID: NCT02224560

Public ClinicalTrials.gov record NCT02224560. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.

Study identification

NCT ID: NCT02224560
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Jazz Pharmaceuticals; Industry
Enrollment: 225 participants

Conditions and interventions

Conditions

Interventions

GWP42003-P Drug
Placebo control Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 7, 2015
Primary completion: May 18, 2016
Completion: May 18, 2016
Last update posted: Sep 27, 2022

2015 – 2016

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Phoenix	Arizona	85054	—
Not listed	Los Angeles	California	90027	—
Not listed	Hartford	Connecticut	06106	—
Not listed	Orlando	Florida	32819	—
Not listed	Augusta	Georgia	30912	—
Not listed	Boise	Idaho	83702	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Buffalo	New York	14222	—
Not listed	New York	New York	10003	—
Not listed	New York	New York	10016	—
Not listed	Clemmons	North Carolina	27012	—
Not listed	Winston-Salem	North Carolina	27157	—
Not listed	Cincinnati	Ohio	45267	—
Not listed	Columbus	Ohio	43205	—
Not listed	York	Pennsylvania	17403	—
Not listed	Charleston	South Carolina	29425	—
Not listed	Austin	Texas	78723	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Charlottesville	Virginia	22903	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02224560, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 27, 2022 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02224560 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →